Yolanda Barbáchano

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González de Castro et al. · The Lancet Oncology · 2013 · 728 citations

Medicine, Oncology, Pharmacology +13

Guidelines for the Content of Statistical Analysis Plans in Clinical Trials

Carrol Gamble, Ashma Krishan, Deborah Stocken et al. · JAMA · 2017 · 583 citations · Full text

Public Health, Biostatistics, Clinical Research Regulation +16

Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer

N J Smith, Yolanda Barbáchano, A. Norman et al. · British journal of surgery · 2007 · 455 citations · Full text

Medicine, Oncology, Radiology +17

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)

Alice Dewdney, David Cunningham, Josep Tabernero et al. · Journal of Clinical Oncology · 2012 · 390 citations · Full text

Medicine, Oncology, Surgery +17

Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial

Yu Jo Chua, Yolanda Barbáchano, David Cunningham et al. · The Lancet Oncology · 2010 · 319 citations

Medicine, Oncology, Surgery +17